Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Cancer|March 15, 2006
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyHagop Kantarjian, Jean-Pierre J Issa, Craig S Rosenfeld, et al.
Leukemia Research|June 19, 2004
Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expressionAzra Raza, Silvia Buonamici, Laurie Lisak, et al.
Cancer Discovery|January 20, 2022
Subversion of Serotonin Receptor Signaling in Osteoblasts by Kynurenine Drives Acute Myeloid LeukemiaMarta Galán-Díez, Florence Borot, Abdullah Mahmood Ali, et al.
Nature|January 17, 2014
Leukaemogenesis induced by an activating β-catenin mutation in osteoblastsAruna Kode, John S Manavalan, Ioanna Mosialou, et al.
Cancer|March 19, 2016
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignanciesGautam Borthakur, Leslie Popplewell, Michael Boyiadzis, et al.
Blood|August 21, 2014
Inhibition of leukemia cell engraftment and disease progression in mice by osteoblastsMaria Krevvata, Barbara C Silva, John S Manavalan, et al.
Leukemia|January 12, 2026
Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstatValeria Santini, Amer M Zeidan, Koen Van Eygen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2020
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II StudyDavid P Steensma, Pierre Fenaux, Koen Van Eygen, et al.
Blood|September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.
Cancer Cell|September 14, 2016
Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome ModulationEsther A Obeng, Ryan J Chappell, Michael Seiler, et al.
Pageof 10